Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol

INTRODUCTION: Patients with breast cancer with homologous recombination deficiency (HRD) such as germline BRCA1/2 mutations would respond to DNA-damaging drugs. Several clinical studies have revealed that HRD biomarkers were associated with the outcomes of patients with early breast cancer (EBC). Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Hao, Pei, Wendi, Zhong, Jianxin, Li, Huiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394194/
https://www.ncbi.nlm.nih.gov/pubmed/35981778
http://dx.doi.org/10.1136/bmjopen-2021-059538

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394194/
https://www.ncbi.nlm.nih.gov/pubmed/35981778
http://dx.doi.org/10.1136/bmjopen-2021-059538

Ejemplares similares